Full-Time
Ultrasound Clinical Sales Specialist
Updated on 9/12/2026
GE Healthcare
1-10 employees
Imaging, monitoring, and healthcare IT solutions
Compensation Overview
$98.4k - $147.6k/yr
No H1B Sponsorship
Remote in USA
Remote
Must live within the territory covering Washington, Oregon, Wyoming, Montana, Alaska, Hawaii, and Idaho; travel is required 70% of the time.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to GE Healthcare
See people who can refer or advise you
- Preferred ARDMS, CCI certification, or a global equivalent.
- Experience in echocardiography, including all clinical applications and performing procedures.
- At least five years of experience in the medical industry.
- Ability to work independently and within a team.
- Customer contact experience in various situations.
- Must live within the territory covering Washington, Oregon, Wyoming, Montana, Alaska, Hawaii, and Idaho.
- Ability to travel 70% of the time.
- Strong organizational, written, and verbal communication skills.
- Must be legally authorized to work in the United States.
- Must complete a drug screen, as applicable.
- Act as a clinical expert within the ultrasound imaging space using a consultative sales approach to develop departmental partnerships with decision makers and collaborate with GE Healthcare counterparts.
- Provide industry-leading support for the development of ultrasound-enhancing agents in echocardiography exams.
- Deliver in-service education presentations to customers in large and small group settings.
- Provide product demonstrations to customers.
- Create business plans for the territory, including opportunity development and competitive strategies.
- Develop and foster a network of thought leaders within the territory, track and communicate market trends to and from the field, and lead effective counterstrategies based on competitor data.
- Integrate with internal support teams and drive meaningful change and impact in customer departments for each patient.
- Provide clinical support for the development of ultrasound-enhancing agents.
- Assist with trials, implementation, training, and echocardiography ultrasound-enhancing agents.
- Differentiate the assigned product offering during various stages of the sales process using approved product marketing and promotion materials to support customer decision-making.
- Demonstrate sales and presentation skills in one-on-one and formal large-group settings, both in person and virtually.
- Represent and assist at local, regional, or national trade shows and meetings as required.
- A bachelor's degree or five years of equivalent experience.
- Ultrasound-enhancing agent application experience.
- Living in Washington or Oregon.
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
- Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
- Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.
What critics are saying
- Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
- Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
- If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.
What makes GE Healthcare unique
- Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
- GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
- The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.
GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.
GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.
GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.